文献速递自身免疫性与大疱性皮肤病

达雷妥尤单抗治疗利妥昔单抗难治性天疱疮

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.
PubMed 文献 · J Invest Dermatol · 2026-06-18

本文报道2例对利妥昔单抗及替代治疗难治的危及生命的天疱疮患者,接受抗CD38单抗达雷妥尤单抗治疗后获得成功,并进行了纵向临床与免疫学监测。利妥昔单抗失败与B细胞清除不完全、记忆B细胞和浆母细胞持续存在相关;达雷妥尤单抗诱导快速临床改善、CD38+浆细胞清除及抗桥粒芯抗体下降。1例停药后复发且因抗利妥昔单抗抗体致利妥昔单抗无效,联合达雷妥尤单抗与贝利尤单抗后获持续完全缓解;另1例达雷妥尤单抗诱导缓解后加用利妥昔单抗巩固。未观察到治疗相关不良事件。

要点

  • 达雷妥尤单抗单用或联合B细胞靶向药或为难治性天疱疮提供新选择
  • 利妥昔单抗难治可能与B细胞清除不完全、记忆B细胞和浆母细胞持续存在有关
  • 达雷妥尤单抗可快速清除CD38+浆细胞并降低抗桥粒芯抗体

核心结论

  • 达雷妥尤单抗单用或联合B细胞靶向药物,可能是利妥昔单抗难治性天疱疮有前景的治疗策略。

研究设计与样本

  • 本文为2例利妥昔单抗及替代治疗难治的危及生命天疱疮患者的病例报告,含纵向临床与免疫学监测。

主要发现

  • 利妥昔单抗治疗失败与B细胞清除不完全、记忆B细胞和浆母细胞持续存在相关。
  • 达雷妥尤单抗诱导快速临床改善、CD38+浆细胞清除及抗桥粒芯抗体下降。
  • 1例停用达雷妥尤单抗后复发,因抗利妥昔单抗抗体致利妥昔单抗无效;联合达雷妥尤单抗与贝利尤单抗后获持续完全缓解。
  • 另1例达雷妥尤单抗诱导的缓解经追加利妥昔单抗巩固。
  • 未观察到治疗相关不良事件。

关键数值与推荐

  • 利妥昔单抗联合短期糖皮质激素是天疱疮标准一线治疗。

临床怎么用

  • 对利妥昔单抗难治的天疱疮,可考虑达雷妥尤单抗单用或联合B细胞靶向药物。
  • 治疗中可监测CD38+浆细胞及抗桥粒芯抗体水平以评估免疫学应答。
  • 达雷妥尤单抗停药后需警惕复发,联合贝利尤单抗可能有助于维持持续完全缓解。

局限性

  • 证据仅来自2例病例报告,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab combined with short-term corticosteroids is the standard first-line treatment for pemphigus, but a subset of patients remains refractory, with limited effective alternatives. Daratumumab, an anti-CD38 mAb targeting plasma cells, has emerged as a potential option in severe autoimmune diseases. We report 2 cases of life-threatening pemphigus refractory to rituximab and alternative therapies that were successfully treated with daratumumab, with longitudinal clinical and immunological monitoring of antidesmoglein responses. Rituximab failure was associated with incomplete B-cell depletion, with the persistence of memory B cells and plasmablasts. Daratumumab induced rapid clinical improvement, depletion of CD38+ plasma cells, and a reduction of antidesmoglein antibodies. In 1 patient, relapse occurred after daratumumab discontinuation, with subsequent rituximab inefficacy due to antirituximab antibodies; combined daratumumab and belimumab led to sustained complete remission, likely through complementary targeting of plasma cells and the prevention of autoreactive B-cell reconstitution. In the second patient, remission induced by daratumumab was consolidated with additional rituximab. No treatment-related adverse events were observed. These findings suggest that daratumumab, alone or in combination with B-cell-targeting agents, may represent a promising therapeutic strategy for rituximab-refractory pemphigus.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Maho-Vaillant M, Lefebvre A, Golinski ML, et al. Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus. J Invest Dermatol. 2026. PMID: 42314934. doi:10.1016/j.jid.2026.06.1274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。